Regulation Impact Statement Updates

Official website for publishing regulatory impact analysis information for regulatory decisions announced by the Australian Government, COAG and COAG Councils.

Clarifying eligibility for origin claims in the Complementary Medicines Sector

COAG
17th October 2019

COAG Consultation Regulation Impact Statement - Governance Forum on Consumer Affairs (CAF)

On 3 October 2019, the Department of Industry, Innovation and Science released a Council of Australian Government’s Regulation Impact Statement (RIS) for consultation on appropriate Country of Origin Labelling for Australian complementary medicines.

The RIS considers the tension between regulation of certain complementary medicines manufactured in Australia under one Australian Law and regulated by the Therapeutic Goods Administration; and under the Australian Consumer Law and eligibility requirements for access to the Australian Made, Australian Grown (AMAG) logo when making an origin claim.

The RIS explores options which reflect quality assurance and product safety balanced with consumer protections and perceptions, including maintenance of the status quo, self-regulation by industry, and changing the Australian Consumer Law to allow Australian manufactured complementary medicines made substantially or entirely from imported ingredients to have access to the AMAG logo.

The Consultation RIS has been assessed by the Office of Best Practice Regulation as compliant with the Council of Australian Government’s Best Practice Regulation requirements.

Comments on this Consultation RIS are invited by close of business 30 October 2019. More information on the consultation process, including how to make a submission, can be found here.

Back to all Updates